NR3C2 and cardiac hypertrophy: Non-aldosterone-mediated activation of the mineralocorticoid receptor (MR) promotes reactive oxygen species generation and mediates tissue inflammation and fibrosis, leading to myocardial hypertrophy, ventricular remodeling, glomerular hypertrophy and glomerulosclerosis, ultimately causing renal-cardiac adverse outcomes [112,113].